Jonathane Ricci Recognized by Lawyers of Distinction, Featured in The Washington Post
TORONTO , ONTARIO, CANADA, June 16, 2025 / EINPresswire.com / -- As prominently featured in The Washington Post, Lawyers of Distinction has recognized Jonathane Ricci, CEO and Founder of JR Wealth Management, in its prestigious 'Most Influential Lawyers' list for 2025. This acknowledgment highlights his significant impact in international tax and wealth management, specifically noting his managed expertise in International Tax and Asset Protection in New York, NY.
This notable inclusion underscores Ricci's pioneering achievements and substantial influence within the legal field, as determined by industry leaders and peers.
'This recognition affirms our commitment to setting new industry benchmarks,' said Jonathane Ricci. 'By blending innovative legal and financial strategies, we continue to deliver exceptional value to our clients, especially in complex international tax and asset protection scenarios.'
This feature in The Washington Post amplifies JR Wealth Management's standing at the forefront of international legal and financial innovation.
About JR Wealth Management
JR Wealth Management combines elite managed legal know-how and know-when with sophisticated wealth management strategies, delivering institutional-grade solutions through a boutique approach. Our proprietary methodologies integrate advanced tax optimization, strategic asset protection, and innovative wealth building frameworks, ensuring intergenerational prosperity for high-net-worth individuals and family offices.
Jonathane Ricci
JR Wealth Management
+1 855-571-3669
email us here
Visit us on social media:
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
34 minutes ago
- Bloomberg
Odd Lots: Eating Steak With Nassim Taleb and Charlie McElligott
Author Nassim Nicholas Taleb and Nomura strategist Charlie McElligott are well-known for their opinions on things like trading, risk and uncertainty. But they also have very strong opinions on food! Nassim famously talks a lot about squid ink pasta, for instance, while Charlie is a well-known meat lover. So we thought we'd invite them to a special meal, one that would be recorded live onstage at our recent event in New York. This is a special subscriber-only bonus episode of our live steak-eating session, in which Nassim and Charlie talk about what makes a good meal, how their respective diets have evolved over the years, plus a near-death experience involving brisket.
Yahoo
40 minutes ago
- Yahoo
Colchester selects design for pedestrian bridge at Fundy Discovery Site
A historic route across the Salmon River in Colchester County is being restored with the addition of a multi-million dollar pedestrian bridge at the Fundy Discovery Site, which is part of the Cliffs of Fundy UNESCO Global Geopark. A decade ago, the Municipality of Colchester acquired the former motel property in Lower Truro. Since then, amenities such as a playground and an amphitheatre have been built. A tidal bore viewing platform is also under construction this summer. Colchester Mayor Christine Blair said there have long been plans for a bridge across the river, but two previous tenders were over the $11-million budget. The suspension bridge design yielded price tags between $17.5 million and $27 million. To lower costs, the municipality instead pursued a design-build tender and received federal approval for pier installation in the river. On June 25, council voted seven to five to pursue a $7.9-million, three-pier, wooden bridge with a curved design. The municipality will be responsible for just over a quarter of project costs with funding for the remainder secured from the federal government. "I've had people stopping me in the grocery store ... saying what a great looking bridge this will be," Blair said in an interview. "Now it'll probably take a couple of years to get it in, but you know, it's going to be there and I think it will be great for the walkers and the bikers and so on." The submission by builder WRD & TRS estimates construction will be completed as early as January 2027. When it opens, it will reinstate pedestrian crossing at the location. According to a staff report, a bridge was established in the 1850s linking Onslow to Lower Truro. The crossing was removed after the construction of Highway 102 in 1970. Even after years of consideration, not all taxpayers agree with the plan to spend millions on a pedestrian bridge. "There's people on both sides of the fence or both sides of the bridge," Coun. Laurie Sandeson, who represents Lower Truro where the Fundy Discovery Site is located, said ahead of the council decision. "And some really want it and some know that we need our roads fixed. We need housing to be a priority." Blair said the pedestrian bridge, which will be closed to motorized vehicles, will advance active transportation in the municipality by connecting Onslow to the Cobequid Trail. She said the infrastructure in view of Highway 102 will also be a valuable tourist attraction. "It's very important for our Cliffs of Fundy UNESCO Global Geopark, for tourism, for economic development," she said. WATCH | Atlantic Canada sites could lose status as UNESCO Geoparks: The bridge plans come as the UNESCO Global Geopark evaluators are expected to assess the Cliffs of Fundy sites this month. The geopark, which stretches along the coast in Cumberland and Colchester counties, was first designated in 2020, but received a yellow rating in its most recent evaluation. In response to recommendations, both county governments have committed to annual funding for the geopark through to 2028. A new website was launched last fall, promotional material was created and trilingual interpretive panels are being installed in preparation for the evaluation. "We're hoping that the improvements that we have made will be nice for them to see and to recognize that we have taken the recommendations seriously and have followed through," said Blair. MORE TOP STORIES
Yahoo
an hour ago
- Yahoo
Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best hot stocks to buy according to Wall Street analysts. On July 3, Bloomberg News reported that AstraZeneca (NASDAQ:AZN) is in discussions with Summit Therapeutics for a licensing agreement concerning an experimental lung cancer drug, with a potential value of up to $15 billion. The proposed deal for the drug, which is known as ivonescimab, could involve an upfront payment of several billion dollars to Summit, in addition to future milestone payments. However, the talks are ongoing and could still fall apart. Summit might even choose to partner with a different company. Neither Summit nor AstraZeneca has officially commented on the report. A laboratory employee in a sterile environment inspecting a microscope focused on a Clostridioides difficile infection sample. Summit Therapeutics secured the rights to ivonescimab through a separate deal worth up to $5 billion with China-based Akeso in December 2022. Under that agreement, Summit gained exclusive rights to develop and commercialize ivonescimab in the US, Canada, Europe, and Japan, while Akeso (OTC:AKESF) retained rights for other regions, including China. The deal included an upfront payment of $500 million to Akeso and potential regulatory and commercial milestones of up to $4.5 billion. Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company that discovers, develops, and commercializes patient, physician, caregiver, and societal-friendly medicinal therapies. AstraZeneca (NASDAQ:AZN) is a biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines. While we acknowledge the potential of SMMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
